Naoko Sanuki1, Atsuya Takeda1, Yohei Oku1, Takahisa Eriguchi2, Shuichi Nishimura2, Yosuke Aoki2, Tomikazu Mizuno3, Shogo Iwabuchi4, Etsuo Kunieda5. 1. Radiation Oncology Center, Ofuna Chuo Hospital, Kanagawa, Japan; Department of Radiation Oncology, Tokai University, Kanagawa, Japan. 2. Radiation Oncology Center, Ofuna Chuo Hospital, Kanagawa, Japan. 3. Department of Radiology, Ofuna Chuo Hospital, Kanagawa, Japan. 4. Department of Hepatology and Gastroenterology, Ofuna Chuo Hospital, Kanagawa, Japan. 5. Department of Radiation Oncology, Tokai University, Kanagawa, Japan. Electronic address: kunieda-mi@umin.ac.jp.
Abstract
PURPOSE: Focal liver reaction (FLR) appears on radiographic images after stereotactic ablative body radiation therapy (SABR) in patients with hepatocellular carcinoma (HCC) and chronic liver disease. We investigated the threshold dose (TD) of FLR and possible factors affecting the TD on gadoxetate acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI). METHODS AND MATERIALS: In 50 patients who were treated with SABR for small HCC and followed up by MRI for >6 months, FLR, seen as a hypointense area, was evaluated on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI. The follow-up MRI with the largest extent of FLR was fused to the planning computed tomography (CT) image, and patients with good image fusion concordance were eligible. After delineating the border of the FLR manually, a dose-volume histogram was used to identify the TD for the FLR. Clinical and volumetric factors were analyzed for correlation with the TD. RESULTS: A total of 45 patients were eligible for analysis with a median image fusion concordance of 84.9% (range, 71.6-95.4%). The median duration between SABR and subsequent hepatobiliary phase MRI with the largest extent of FLR was 3 months (range, 1-6 months). The median TD for FLR was 28.0 Gy (range, 22.3-36.4 Gy). On univariate analysis, pre-treatment Child-Pugh (CP) score and platelet count were significantly correlated with the TD. On multiple linear regression analysis, CP score was the only parameter that predicted TD. Median TDs were 30.5 Gy (range, 26.2.3-36.4 Gy) and 25.2 Gy (range, 22.3-27.5 Gy) for patients with CP-A and CP-B disease, respectively. CONCLUSION: The TD was significantly correlated with baseline liver function. We propose 30 Gy for CP-A disease and 25 Gy for CP-B disease in 5 fractions as TDs for FLR after SABR for patients with HCC and chronic liver disease. Use of these TDs will help to predict potential loss of liver tissue after SABR.
PURPOSE: Focal liver reaction (FLR) appears on radiographic images after stereotactic ablative body radiation therapy (SABR) in patients with hepatocellular carcinoma (HCC) and chronic liver disease. We investigated the threshold dose (TD) of FLR and possible factors affecting the TD on gadoxetate acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI). METHODS AND MATERIALS: In 50 patients who were treated with SABR for small HCC and followed up by MRI for >6 months, FLR, seen as a hypointense area, was evaluated on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI. The follow-up MRI with the largest extent of FLR was fused to the planning computed tomography (CT) image, and patients with good image fusion concordance were eligible. After delineating the border of the FLR manually, a dose-volume histogram was used to identify the TD for the FLR. Clinical and volumetric factors were analyzed for correlation with the TD. RESULTS: A total of 45 patients were eligible for analysis with a median image fusion concordance of 84.9% (range, 71.6-95.4%). The median duration between SABR and subsequent hepatobiliary phase MRI with the largest extent of FLR was 3 months (range, 1-6 months). The median TD for FLR was 28.0 Gy (range, 22.3-36.4 Gy). On univariate analysis, pre-treatment Child-Pugh (CP) score and platelet count were significantly correlated with the TD. On multiple linear regression analysis, CP score was the only parameter that predicted TD. Median TDs were 30.5 Gy (range, 26.2.3-36.4 Gy) and 25.2 Gy (range, 22.3-27.5 Gy) for patients with CP-A and CP-B disease, respectively. CONCLUSION: The TD was significantly correlated with baseline liver function. We propose 30 Gy for CP-A disease and 25 Gy for CP-B disease in 5 fractions as TDs for FLR after SABR for patients with HCC and chronic liver disease. Use of these TDs will help to predict potential loss of liver tissue after SABR.
Authors: Judit Boda-Heggemann; Ulrike Attenberger; Johannes Budjan; Anika Jahnke; Lennart Jahnke; Lena Vogel; Anna O Simeonova-Chergou; Carsten Herskind; Frederik Wenz; Frank Lohr Journal: Strahlenther Onkol Date: 2016-07-08 Impact factor: 3.621
Authors: Judit Boda-Heggemann; Anika Jahnke; Mark K H Chan; Leila S Ghaderi Ardekani; Peter Hunold; Jost Philipp Schäfer; Stefan Huttenlocher; Stefan Wurster; Dirk Rades; Guido Hildebrandt; Frank Lohr; Jürgen Dunst; Frederik Wenz; Oliver Blanck Journal: Strahlenther Onkol Date: 2018-02-05 Impact factor: 3.621
Authors: Zhao-Chong Zeng; Jinsil Seong; Sang Min Yoon; Jason Chia-Hsien Cheng; Ka-On Lam; Ann-Shing Lee; Ada Law; Jian-Ying Zhang; Yong Hu Journal: Liver Cancer Date: 2017-08-30 Impact factor: 11.740
Authors: Mary Feng; Krithika Suresh; Matthew J Schipper; Latifa Bazzi; Edgar Ben-Josef; Martha M Matuszak; Neehar D Parikh; Theodore H Welling; Daniel Normolle; Randall K Ten Haken; Theodore S Lawrence Journal: JAMA Oncol Date: 2018-01-01 Impact factor: 31.777